• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

Erythropoietin prophylaxis unlikely to improve neurodevelopment in very preterm infants

byDaniel FisherandMichael Milligan
May 18, 2016
in Neurology, Pediatrics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Very preterm infants who were given high dose recombinant human erythropoietin (rhEPO) after birth did not show improved neurodevelopmental outcomes at two years of follow-up.

2. Survival without severe neurodevelopmental impairment was also not improved in the rhEPO group compared to the placebo controls.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Infants born at 26 to 32 weeks of age (very early preterm) demonstrate poorer neurodevelopmental outcomes compared to those born later during the gestational period. Previous studies have shown that recombinant human erythropoietin (rhEPO) may be neuroprotective when administered at high doses prophylactically after birth. In this randomized controlled trial, two groups of very preterm infants received either three doses of rhEPO or placebo within a 42 hour period after birth. At two years of follow up, infants who received rhEPO did not demonstrate better outcomes on a neurodevelopmental assessment index compared to placebo. Secondary outcomes and exploratory analyses, including measures of psychomotor function, mean body weight and length, head circumference, and severe visual or hearing impairment, were also not significantly different between groups. Both groups showed similar rates of survival without neurodevelopmental impairments.

These results do not lend support for the theory that rhEPO is beneficial for neurodevelopmental outcomes in very preterm infants. However, it is not clear what effects early rhEPO prophylaxis might have at later time points or whether more prolonged doses of rhEPO might be beneficial. Other ongoing clinical trials utilizing different dosing regimens and measuring outcomes at different time points may reveal more effective strategies for rhEPO prophylaxis in very preterm infants.

Click to read the study, published today in JAMA

Relevant Reading: Association Between Early Administration of High-Dose Erythropoietin in Preterm Infants and Brain MRI Abnormality at Term-Equivalent Age

RELATED REPORTS

#VisualAbstract: A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants

High dose erythropoietin may not be efficacious for neuroprotection in extremely preterm infants

Erythropoietin linked with reduced risk of brain injury in preterm infants

In-Depth [randomized controlled trial]: A total of 450 very preterm infants (born between 26 weeks 0 days and 31 weeks 6 days of gestation) were recruited across 5 Swiss hospitals to receive either 3000 IU/kg rhEPO or placebo in 3 doses at 3 hours, 12 – 18 hours, and 36 – 42 hours after birth. Infants with severe congenital malformations, genetically defined syndromes, severe intraventricular hemorrhage, or a prior palliative care consult were excluded. At two years of follow up, the rhEPO (83% follow-up) and placebo (79% follow-up) groups were given neurodevelopmental examinations using the Bayley Scales of Infant Development-II (BSID-II), Mental Development Index (MDI), and Psychomotor Development Index (PDI), among others. The rhEPO group did not show a statistically significant difference on the MDI (Difference: -1; CI95 -4.5 to 2.5) or PDI (Difference: -2.6; CI99 -7.7 to 1.7) compared to the placebo group. In addition, there were no statistically significant differences in the rate of neurodevelopmental disorders, visual or hearing impairment, or measures of weight, length, and head circumference. The rate of survival without neurodevelopmental impairment was also similar between the two groups (OR = 0.9; CI99 0.4 to 1.9).

 

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: erythropoietin
Previous Post

Fewer work hours linked to greater likelihood of continued breastfeeding

Next Post

2 Minute Medicine Rewind May 16, 2016

RelatedReports

#VisualAbstract: A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants
StudyGraphics

#VisualAbstract: A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants

February 4, 2020
Quick Take: Analgesic efficacy and safety of morphine in the Procedural Pain in Premature Infants (Poppi) study: randomised placebo-controlled trial
Neurology

High dose erythropoietin may not be efficacious for neuroprotection in extremely preterm infants

January 17, 2020
Erythropoietin linked with reduced risk of brain injury in preterm infants
Neurology

Erythropoietin linked with reduced risk of brain injury in preterm infants

August 27, 2014
Next Post
Government-funded initiatives provide important supports to low-income HIV patients

2 Minute Medicine Rewind May 16, 2016

Smoking during pregnancy associated with aerobic fitness of children

Risk-based computed tomography screening for lung cancer may be superior to current screening guidelines

Certain financial incentive programs may promote increased physical activity

Physical activity associated with lower cancer risk

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.